Physician profile
Chin Tang
NPI 1023245198
$4,810.88
in general payments reported to CMS, 2019-2025
22 companies · $1,096 in 2025
The $1,096 reported for 2025 was more than what 82% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $102 · 2020: $240 · 2021: $675 · 2022: $973 · 2023: $1,271 · 2024: $455 · 2025: $1,096.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,821.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,820.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $697.44 | 2020-2025 | Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $599.11 | 2019-2023 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $586.98 | 2021-2023 | |
| Axsome Therapeutics, INC. | $368.82 | 2025 | Auvelity, Symbravo |
| Glaxosmithkline, LLC. | $360.27 | 2023-2025 | Arexvy, Shingrix |
| Corcept Therapeutics | $296.62 | 2023-2025 | Korlym |
| Novo Nordisk INC | $215.23 | 2021-2023 | Wegovy |
| Sanofi-Aventis U.S. LLC | $205.11 | 2022-2023 | |
| Amgen INC. | $140.95 | 2024 | Krystexxa |
| Otsuka America Pharmaceutical, INC. | $124.99 | 2024 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $124.99 | 2025 | Austedo Xr |
| Abbvie INC. | $124.83 | 2022 | |
| Genentech USA, INC. | $123.50 | 2021 | |
| Merck Sharp & Dohme LLC | $122.31 | 2022 | |
| Phathom Pharmaceuticals, INC. | $121.91 | 2025 | Voquezna |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $114.70 | 2022 | |
| Idorsia Pharmaceuticals US INC | $112.71 | 2023 | Quviviq |
| Biohaven Pharmaceutical Holding Company LTD. | $108.75 | 2022 | |
| Horizon Therapeutics Plc | $107.02 | 2023 | Krystexxa |
| Janssen Pharmaceuticals, INC | $65.66 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $49.89 | 2020 | |
| Nestle Healthcare Nutrition INC. | $39.09 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chin Tang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.